Master of Science (MS)
Biochemistry & Molecular Biology
Rebecca Oberley-Deegan, Ph.D.
Prostate cancer is the second leading cause of cancer related deaths in men in the United States. Treatment for prostate cancer, such as androgen deprivation therapy, radiation, and surgery are effective until resistant cells arise and develop castration resistant prostate cancer (CRPC). CRPC is often difficult to treat due to androgen-independent signaling and growth. Here we target the altered redox balance in prostate cancer with MnTnBuOE-2-PyP (BuOE), a superoxide dismutase (SOD) mimic and ADT treatments. We investigated prostate cancer growth with BuOE and multiple ADT treatments in CRPC cell line models, C42B and 22Rv1. Our results show BuOE and ADT treatments can have a synergistic effect on decreasing prostate cancer growth, although the exact molecular mechanism remains unknown. We further confirmed our in vitro findings with BuOE and ADT in an in vivo model.
Moats, Ariel, "MnTnBuOE-2-PyP Sensitizes Castrate Resistant Prostate Cancer to Androgen Deprivation Therapies" (2023). Theses & Dissertations. 731.